Journal of the American Academy of Dermatology

Papers
(The H4-Index of Journal of the American Academy of Dermatology is 56. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases645
Immune checkpoint inhibitor–related dermatologic adverse events256
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial242
Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies170
Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis169
Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures154
Hand hygiene during COVID-19: Recommendations from the American Contact Dermatitis Society149
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 143
Oral minoxidil treatment for hair loss: A review of efficacy and safety141
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 i125
Skin color in dermatology textbooks: An updated evaluation and analysis122
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results117
Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study114
United States burden of melanoma and non-melanoma skin cancer from 1990 to 2019108
Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor–modulating agent104
Visible light. Part I: Properties and cutaneous effects of visible light102
Photoprotection beyond ultraviolet radiation: A review of tinted sunscreens101
Prurigo nodularis99
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)93
Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: A systematic review92
Infantile hemangioma. Part 1: Epidemiology, pathogenesis, clinical presentation and assessment91
COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence89
Prurigo nodularis88
Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis85
Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations84
The digital divide: How COVID-19's telemedicine expansion could exacerbate disparities84
Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients84
National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 83
Occupational dermatitis to facial personal protective equipment in health care workers: A systematic review83
The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study80
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 80
Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study79
Facial and neck erythema associated with dupilumab treatment: A systematic review79
American Academy of Dermatology Guidelines: Awareness of comorbidities associated with atopic dermatitis in adults78
The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: A systematic analysis from the Global Burden of Disease Study 201776
Guidelines of care for the management of actinic keratosis76
Association between alopecia areata, anxiety, and depression: A systematic review and meta-analysis70
The ongoing racial disparities in melanoma: An analysis of the Surveillance, Epidemiology, and End Results database (1975-2016)69
Cutaneous adverse events caused by immune checkpoint inhibitors69
Treatments and outcomes of generalized pustular psoriasis: A cohort of 1516 patients in a nationwide inpatient database in Japan67
Infantile hemangioma. Part 2: Management67
Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study66
Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis65
Treating toxic epidermal necrolysis with systemic immunomodulating therapies: A systematic review and network meta-analysis64
Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis63
Visible light. Part II: Photoprotection against visible and ultraviolet light62
Itch: Pathogenesis and treatment61
The clinical spectrum of COVID-19–associated cutaneous manifestations: An Italian multicenter study of 200 adult patients60
Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus60
Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis60
Management of inadequate response and adverse effects to dupilumab in atopic dermatitis60
Skin cancer: Primary, secondary, and tertiary prevention. Part I58
Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group57
Immune checkpoint inhibitors to treat cutaneous malignancies57
Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry56
Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma56
0.052133798599243